News

The pre-clinical research was presented at the 8th International M Judah Folkman Conference in Cambridge, Massachusetts, highlighting significant advances in the systemic delivery of RNAi therapeutics. In the

In the study, BSI-201demonstrated that treatment with the drug in combination with gemcitabine/carboplatin results in a improvement in overall survival and a high rate of clinical response in

Prior to joining PepTcell, Scheske served as president of Consumer Healthcare Europe at GlaxoSmithKline (GSK) for over 25 years. Scheske, who was president of GSK’s European Consumer Healthcare

FDA said that Sibutramine is not listed on the product label and could harm consumers, especially those with cardiovascular conditions. FDA lab tests revealed that the product contains

Bexion Pharma has received the Phase II SBIR grant to identify and select optimised SapC-DOPS formulations and treatment methods for glioblastoma multiforme, suitable for advancing Bexion’s drug toward

OpRegen is a proprietary formulation of embryonic stem cell-derived retinal pigment epithelial cells designed by Cell Cure to help save the sight of the baby boomer generation. The

In September 2008, Merck Serono and Ablynx entered into an agreement to co-discover and co-develop nanobodies against two targets in oncology and immunology. Merck Serono and Ablynx’s new

Results from the LUX-Lung 1 trial suggest that Afatinib is highly active in late-stage patients with NSCLC1, while in the LUX-Lung 2 Phase II trial Afatinib demonstrated encouraging

Under the first agreement, Exelixis will grant to BMS an exclusive license to its small-molecule TGR5 agonist program including backups. Under the second agreement, the companies will collaborate